FDA Approves Keytruda for First-Line Treatment of PD-L1–Expressing Metastatic NSCLC

Worth it? A faster transplant but a kidney with hepatitis C
November 14, 2016
Age of onset for multiple sclerosis ‘linked to distance from equator’
November 15, 2016
Show all

FDA Approves Keytruda for First-Line Treatment of PD-L1–Expressing Metastatic NSCLC

The FDA has approved a test to determine which patients are appropriate for Keytruda as the first-line treatment of metastatic non–small cell lung cancer.

The FDA granted approval to pembrolizumab for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors express programmed death ligand-1 as determined by an FDA–approved test.

Atezolizumab (Tecentriq, Genentech) — the first and only FDA–approved anti–PD-L1 cancer immunotherapy — is intended for patients with urothelial carcinoma who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.

“Tecentriq is a new medicine that can work with the immune system to treat people with a type of bladder cancer that progressed after platinum-based chemotherapy,” Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, said in a press release. “We thank the scientists, doctors, patients and their families who made it possible to bring Tecentriq to people with advanced urothelial carcinoma.”

Read Full Article: FDA Approves Keytruda for First-Line Treatment of PD-L1–Expressing Metastatic NSCLC

Read Full Article: FDA Approves Keytruda for First-Line Treatment of PD-L1–Expressing Metastatic NSCLC

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.